National Reference Laboratory of HIV Molecular Biology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.
Hanoi University of Public Health, Hanoi, Vietnam.
PLoS One. 2020 Apr 9;15(4):e0230968. doi: 10.1371/journal.pone.0230968. eCollection 2020.
Access to HIV viral load is crucial to efficiently monitor patients on antiretroviral treatment (ART) and prevent HIV drug resistance acquisition. However, in some remote settings, access to viral load monitoring is still complex due to logistical and financial constraints. Use of dried blood spots (DBS) for blood collection could overcome these difficulties. This study aims to describe feasibility and operability of DBS use for routine viral load monitoring.
From June 2017 to April 2018, HIV-infected adults who initiated ART were enrolled in a prospective cohort in 43 clinical sites across 6 provinces in North Vietnam. Following national guidelines, the first viral load monitoring was planned 6 months after ART initiation. DBS were collected at the clinical site and sent by post to a central laboratory in Hanoi for viral load measurement.
Of the 578 patients enrolled, 537 were still followed 6 months after ART initiation, of which DBS was collected for 397 (73.9%). The median (inter quartile range) delay between DBS collection at site level and reception at the central laboratory was 8 (6-19) days and for 70.0% viral load was measured ≤30 days after blood collection. The proportion of patients with viral load ≥1000 copies/mL at the 6 month evaluation was 15.9% (n = 59). Of these, a DBS was collected again to confirm virological failure in 15 (24.4%) of which virological failure was confirmed in 11 (73.3%).
Delay of DBS transfer to the central laboratory was acceptable and most viral loads were measured in ≤30 days, in-line with routine follow-up. However, the level of DBS coverage and the proportion of patients in failure for whom a confirmatory viral load was available were suboptimal, indicating that integration of viral load monitoring in the field requires, among other things, careful training and strong involvement of the local teams. The proportion of patients experiencing virological failure was in line with other reports; interestingly those who reported being non-adherent and those with a low BMI were more at risk of failure.
获得 HIV 病毒载量对于有效监测接受抗逆转录病毒治疗(ART)的患者和预防 HIV 耐药性的产生至关重要。然而,在一些偏远地区,由于后勤和财务方面的限制,获得病毒载量监测仍然很复杂。使用干血斑(DBS)进行采血可以克服这些困难。本研究旨在描述使用 DBS 进行常规病毒载量监测的可行性和可操作性。
2017 年 6 月至 2018 年 4 月,在越南北部 6 个省的 43 个临床站点,对新开始接受 ART 的 HIV 感染成年人进行了一项前瞻性队列研究。根据国家指南,计划在 ART 开始后 6 个月进行首次病毒载量监测。DBS 在临床站点采集,并通过邮寄寄往河内的中央实验室进行病毒载量测量。
在 578 名入组患者中,537 名患者在 ART 开始后 6 个月仍在随访中,其中 397 名(73.9%)采集了 DBS。DBS 在现场采集与寄往中央实验室之间的中位(四分位距)延迟为 8 天(6-19 天),70.0%的病毒载量在采血后≤30 天内进行了测量。在 6 个月评估时,病毒载量≥1000 拷贝/mL 的患者比例为 15.9%(n=59)。其中,15 名患者再次采集了 DBS 以确认病毒学失败,其中 11 名(73.3%)确认病毒学失败。
DBS 转移至中央实验室的延迟时间是可以接受的,并且大多数病毒载量在≤30 天内进行了测量,符合常规随访要求。然而,DBS 的覆盖率和可供确认的病毒学失败患者比例均不理想,这表明在现场整合病毒载量监测除其他外,还需要对当地团队进行仔细培训和大力支持。发生病毒学失败的患者比例与其他报告相符;有趣的是,那些报告不依从的患者和 BMI 较低的患者发生失败的风险更高。